查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179951

2023-2030 年全球痤疮药物市场

Global Acne Therapeutics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期内 (2023-2030)，痤疮治疗药物的全球市场规模预计将以 4.7% 的复合年增长率增长。

青春期是痤疮最流行的时期，痤疮是一种毛囊炎症性疾病。 以开放性（黑色）和封闭性（白色）粉刺、炎性丘疹、脓疱、结节和囊肿为特征的病变可能会导致瘢痕形成和色素改变。 痤疮的多因素发病机制包括毛囊异常角化、由于高雄激素血症、痤疮丙酸桿菌增殖和炎症引起的皮脂分泌增加。

市场动态

推动全球痤疮药物市场的主要因素是对更快治疗和更好结果的需求不断增长，痤疮相关疾病发病率增加，以及各种痤疮治疗产品，如抗生素和维甲酸。对这种疾病的使用和认识进一步提高影响市场。

对更快治疗和更好结果的需求不断增长，预计将推动市场增长。

由于患者期望更快的治疗和更有效的结果，因此对使用激光等设备进行治疗的需求预计会增长。 激光治疗可防止面部毛髮生长和色素沉着障碍等问题的复发和未来发生。 此外，患者可能很容易适应激光治疗，因为它比其他形式引起的不适更少。 例如 医生建议使用组合药物来永久减少粉刺的产生，例如将外用抗生素与类视黄醇搭配使用。

Dermatology Times，2022 年 AviClear 激光最近获得批准，这是第一款针对皮脂腺并经美国食品和药物管理局 (FDA) 认证可治疗轻度至重度痤疮的设备，是一种基于能量的痤疮治疗方法。I会报告我正在加紧治疗。 研究表明，电热疗法通过选择性地破坏皮脂腺来治疗痤疮是一种安全有效的方法。 一项涉及 63 名患者的随机对照研究发现，以 4 週为间隔接受 3 次电热疗法的治疗组在 12 週时显着减少了炎性痤疮病变，两项独立研究由医生确定。 像这样的研究为使用基于能量的设备治疗痤疮铺平了道路。 “最近的仪器痤疮治疗使用皮脂特定波长。

与痤疮药物相关的副作用预计会阻碍市场增长。

此外，患者转向其他选择以及现有治疗的副作用可能会导致市场收入增长放缓。

COVID-19 影响分析

COVID-19 疫情起源于中国，并已蔓延至世界各地。 几乎每个国家都受到了这一流行病的影响。 大多数国家都实施了封锁以抗击流行病，影响了痤疮药物市场。 大流行减缓了众多行业的经济扩张。 这种感染使世界各地的医疗保健系统不堪重负，出于安全考虑，许多皮肤科诊所对公众关闭。

一些医院和诊所已改造成 COVID-19 中心，使用经大流行病批准的医院结构来治疗和隔离 COVID-19 患者。 封锁还阻止许多患者去药房和皮肤科医生取药。 远程医疗已成为在现代环境中为痤疮患者提供关键皮肤科服务的有效方式。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 对更快治疗和更好结果的需求不断增长
      • 痤疮相关疾病的发病率和痤疮治疗产品的使用率增加
    • 约束因素
      • 与痤疮药物相关的副作用
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 流行率
  • 炎症
  • 系统
  • 术后伤口

第 8 章按治疗类别分类

  • 维甲酸
  • 抗生素
  • 荷尔蒙
  • 联合疗法
  • 其他

第9章给药途径

  • 外部代理
  • 口语
  • 注射

第 10 章分销渠道

  • 零售店
  • 药房/药店
  • 在线商店

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第13章公司简介

  • Sun Pharmaceutical Industries, Inc
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Allergan Plc
  • Galderma S.A
  • Johnson & Johnson
  • Reckitt Benckiser Group
  • Guthy-Renker
  • Stiefel Laboratories
  • Valeant Pharmaceuticals
  • Teva Pharmaceuticals
  • Cutera Inc.

第 14 章全球痤疮药物市场-DataM

简介目录
Product Code: DMPH3600

Market Overview

The global acne therapeutics market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.7% during the forecast period (2023-2030).

Adolescence is the most common time for acne, an inflammatory condition of the pilosebaceous units. Open (black) and closed (white) comedones, inflammatory papules, pustules, nodules, and cysts are the distinctive lesions that may result in scarring and pigmentary alterations. Acne's multifactorial pathophysiology includes aberrant follicular keratinization, increased sebum production by hyperandrogenism, Propionibacterium acnes growth, and inflammation.

Market Dynamics

The major factors driving the global acne therapeutics market are the increasing desire for quicker treatment and better results, increasing incidence of acne-related conditions and the usage of various acne treatment products, including antibiotics and retinoids, and the growing awareness of the condition further influence the market.

An increasing desire for quicker treatment and better results is expected to drive the market's growth.

As patients expect more expedient therapies and effective outcomes, the need for equipment-based therapies like lasers is anticipated to rise. Laser procedures prevent the recurrence of issues, including increased facial hair growth and pigmentation abnormalities and their future occurrence. Additionally, patients might adapt more easily to laser treatments because they are less uncomfortable than other forms. For instance, doctors advise utilizing combination medication to permanently reduce the development of acne, such as pairing a topical antibiotic with a retinoid.

Dermatology Times, 2022 reports the recent clearance of the AviClear laser, which targets sebaceous glands and is the first device certified by the US Food and Drug Administration (FDA) for mild-to-severe, has enhanced the energy-based therapy of acne. Studies have shown that electro thermolysis is a secure and efficient way of treating acne by selectively destroying sebaceous glands. According to a randomized, controlled research including 63 patients, the treatment group, which underwent three electro thermolysis treatments spaced four weeks apart, experienced a significant decrease in inflammatory acne lesions at week 12, as determined by two independent physicians. Such investigations paved the way for using energy-based devices to treat acne. "The most recent developments in device-based acne treatment use wavelengths unique to sebum.

Side effects associated with acne therapeutics are expected to hamper the market's growth.

Additionally, patients switching to other options and the adverse effects of the already accessible treatments may be contributing factors to the market's slow revenue growth.

COVID-19 Impact Analysis

The COVID-19 outbreak originated in China and has spread far over the world. Nearly all countries are affected by the pandemic. As most nations implemented lockdowns to battle the pandemic, this affects the acne therapeutics market. The pandemic has slowed down economic expansion across a wide range of industries. The covid has put a strain on healthcare systems worldwide, and many dermatology clinics are no longer accessible to the public due to safety concerns.

For the treatment and isolation of patients with the covid infection, several hospitals and clinics have been modified into COVID-19 centers using pandemic-approved hospital structures. The lockdown also prevents many patients from getting to pharmacies and dermatologist offices to pick up their prescriptions. Telemedicine has become a viable and effective way to deliver crucial dermatological services to acne patients in the contemporary environment.

Segment Analysis

The retinoid segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The market for acne treatments is anticipated to be dominated by the retinoid segment. The demand for retinoid creams and gels has surged since they successfully treat or prevent mild to moderate acne. After a successful treatment, they can also be used as maintenance therapy to keep the skin clear. Additionally, market participants constantly introduce brand-new and generic retinoids to acquire a competitive edge in the market.

For instance, in March 2022, Twyneo, a cream with tretinoin 0.1% and benzoyl peroxide 3.0%, was approved by the FDA for the topical treatment of acne vulgaris in patients 9 years of age and older. Twyneo is a fixed-dose mixture of the topical antibiotic benzoyl peroxide and the retinoid tretinoin 0.1%. To include the two active ingredients in the cream, Twyneo's formulation uses silica core-shell structures to independently microencapsulate the tretinoin and benzoyl peroxide crystals. The increasing number of retinoid product launches will result in more adoption because of their effectiveness in treating acne, which is anticipated to propel the expansion of this market.

Throughout the projection period, increased research and development for discontinued acne therapies will also benefit expanding this market. For instance, in April 2021, Ortho Dermatologics, a division of Bausch Health specializing in prescription dermatology, released encouraging topline results from its second Phase III trial for IDP-126, a three-compound combination gel tested on 193 people with acne vulgaris. The results showed reductions in both inflammatory and non-inflammatory lesions at week 12 in both conditions. Adapalene, retinol, and the antimicrobial benzoyl peroxide are all included in IDP-126. Such retinoid-related research is anticipated to help the segment's growth by increasing sales and manufacturing of related items.

Global Acne Therapeutics Market- Geographical Analysis

North America holds the largest market share in the global acne therapeutics market.

North America dominates the global acne therapeutics market primarily due to its large population, excellent medical infrastructure, and high-income levels. The key drivers propelling the growth of the acne therapeutics market in North America are the rising prevalence of acne in the region, acquisitions, and recent product introductions. In order to compete with those already on the market, a significant number of key market players are developing new products and technologies, while others are acquiring or partnering with other companies that are in high demand in the acne therapeutics market.

For instance, in December 2021, Sanofi announced an agreement to buy Origimm Biotechnology GmbH, a privately held biotechnology business based in Austria that specializes in identifying pathogenic skin microbiome components and antigens from bacteria that cause skin conditions, including acne. By making this acquisition, Sanofi is continuing to implement its global Play to Win strategy, look for growth possibilities, and develop a portfolio of vaccines that leads the market.

For instance, in November 2021, the US market for Winlevi cream, used to treat acne in individuals 12 years of age and older was announced by Sun Pharmaceutical Industries. Winlevi, a topical androgen receptor inhibitor that is the first of its kind, received FDA approval in August 2020. According to a statement from Sun Pharma, Winlevi is the first FDA-approved acne medication with the first-in-class mechanism of action in nearly 40 years. It prevents the effects of androgen receptors in sebaceous gland cells, which are responsible for creating sebum (oil) and irritation in the skin. It is appropriate for both genders. Therefore, it is anticipated that the market under study in the North American area will be driven by regular product launches and research and development initiatives undergoing the creation of novel acne therapies.

Competitive Landscape

The acne therapeutics market is moderately competitive with local and global companies' presence Sun Pharmaceutical Industries, Inc, Allergan Plc, Galderma S.A, Johnson & Johnson, Reckitt Benckiser Group, Guthy-Renker, Stiefel Laboratories, Valeant Pharmaceuticals

Teva Pharmaceuticals, Cutera Inc, and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in March 2022, The U.S. Food and Drug Administration cleared AviClear, the first and only energy-based device to do so for the treatment of mild, moderate, and severe acne. CUTERA, INC. ("Cutera" or the "Company"), a leading developer of dermatology solutions, released the news.

Sun Pharmaceutical Industries, Inc.

Overview: An extensive selection of pharmaceutical formulations, including branded generics and generic medications, are offered by Sun Pharmaceutical Industries Ltd. (Sun Pharma), a specialty pharmaceutical company. Products for the treatment of psychiatric, neurological, nephrological, gastroenterological, Orthopedic, and ophthalmologic diseases and disorders, as well as cardiac problems, are part of the company's portfolio.

Product Portfolio:

ABSORICA LD (isotretinoin): Under fed conditions, ABSORICA LD 32 mg is bioequivalent to ABSORICA 40 mg. Additionally, ABSORICA LD has a similar safety profile while providing twice the absorption of ABSORICA in a fasting condition. ABSORICA LD is not interchangeable with any other isotretinoin that is currently on the market and offers maximum isotretinoin absorption at a 20% lower dose.

The global acne therapeutics market report would provide access to approx.: 45+ market data tables, 40+ figures, and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing desire for quicker treatment and better results
      • 4.1.1.2. Increasing incidence of acne-related conditions and the usage of various acne treatment products
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with acne therapeutics
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Comedonal
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Inflammatory
  • 7.4. Cystic
  • 7.5. Postsurgical/wound

8. By Therapeutic Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
    • 8.1.2. Market Attractiveness Index, By Therapeutic Class
  • 8.2. Retinoid
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Antibiotic
  • 8.4. Hormonal Agent
  • 8.5. Combination
  • 8.6. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Topical
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Oral
  • 9.4. Injectable

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Retail Store
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Pharmacy & Drug Store
  • 10.4. Online Stores

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Sun Pharmaceutical Industries, Inc
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Allergan Plc
  • 13.3. Galderma S.A
  • 13.4. Johnson & Johnson
  • 13.5. Reckitt Benckiser Group
  • 13.6. Guthy-Renker
  • 13.7. Stiefel Laboratories
  • 13.8. Valeant Pharmaceuticals
  • 13.9. Teva Pharmaceuticals
  • 13.10. Cutera Inc.

LIST NOT EXHAUSTIVE

14. Global Acne Therapeutics Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us